PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

HOSSEINZADEH MOLAYOUSEFI M.; IRAVANI M.; GHAVAMZADEH ARDESHIR; ALI MOGHADAM K.; TOUGHEH GH.R.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ACTA MEDICA IRANICA Year:2006 | Volume:44 | Issue:2 Page(s): 83-88

Download Full-Text

View:

323

Download:

Cites:

Information Journal Paper

Title

PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER

Author(s)

Keywords

NON SMALL CELL LUNG CANCER

GEMCITABINE

CISPLATIN

Abstract

Cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (NSCLC). Many novel drugs have been used in combination with CISPLATIN in this setting. Of these drugs, GEMCITABINE is reported to have a high response rate and acceptable toxicity. The aim of this study was to evaluate the efficacy and safety of GEMCITABINE and CISPLATIN combination. Twenty-three patients with NSCLC were enrolled from January 2001 till September 2003. All of them were confirmed by histology and were in advanced stage, i.e. stage IIIB or stage IV. CISPLATIN with the dose of 70 mg/m2 was given every 21 days, in combination with GEMCITABINE at a dose of 1250 mg/m2 administered on days 1, 8 of a 21-day cycle. Of the 23 patients, 1 showed complete remission, 5 achieved partial remission and 7 had stable disease and 2 patients showed progressive disease, 8 patients were not evaluable for response. The overall response in 15 evaluable patients was 40% (95% CI.), median survival was 13.5 months (95% CI, 3.5-27.4 months), and median progression free survival was 11 months (95% CI, 1.04-20.9 months). Hematological toxicity’s included anemia, neutropenia and thrombocytopenia. Non-hematological toxicities included nausea/vomiting, peripheral neuropathy, skin rashes, mild renal impairment and one case of acute respiratory distress syndrome; another case developed transient acute psychosis. The regimen of combined GEMCITABINE with CISPLATIN is safe and effective and well tolerated in patients. In this combination, a lower dose of CISPLATIN seems to have an efficacy similar to that seen in previous reports.

Cites

No record.

References

Cite

APA: Copy

HOSSEINZADEH MOLAYOUSEFI, M., IRAVANI, M., GHAVAMZADEH, ARDESHIR, ALI MOGHADAM, K., & TOUGHEH, GH.R.. (2006). PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER. ACTA MEDICA IRANICA, 44(2), 83-88. SID. https://sid.ir/paper/277886/en

Vancouver: Copy

HOSSEINZADEH MOLAYOUSEFI M., IRAVANI M., GHAVAMZADEH ARDESHIR, ALI MOGHADAM K., TOUGHEH GH.R.. PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER. ACTA MEDICA IRANICA[Internet]. 2006;44(2):83-88. Available from: https://sid.ir/paper/277886/en

IEEE: Copy

M. HOSSEINZADEH MOLAYOUSEFI, M. IRAVANI, ARDESHIR GHAVAMZADEH, K. ALI MOGHADAM, and GH.R. TOUGHEH, “PHASE II STUDY OF GEMCITABINE AND CISPLATIN IN ADVANCED NON-SMALL CELL LUNG CANCER,” ACTA MEDICA IRANICA, vol. 44, no. 2, pp. 83–88, 2006, [Online]. Available: https://sid.ir/paper/277886/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops